Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06547112
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide G-CSF Mobilization
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide G-CSF Mobilization
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study includes extended CD34 profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad-induction followed by motixafortide G-CSF mobilization and in addition assesses the pharmacodynamics PD of motixafortide following standard 12 hours vs early 16 hours dosing The investigators hypothesize that quad-induction may alter the stem cell subsets within the mobilized graft The investigators further hypothesize that standard and early dosing strategies will result in comparable mobilization and stem cell collection rates
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None